KPTI Shares Outstanding History



Below is a table of the KPTI shares outstanding history going back to 11/6/2013:

Date KPTI Shares Outstanding
11/6/201327.60M
12/16/201329.75M
3/14/201429.75M
4/30/201429.76M
7/31/201432.67M
11/4/201432.70M
3/11/201535.68M
4/30/201535.69M
7/31/201535.71M
11/4/201535.73M
3/7/201635.88M
5/3/201635.96M
7/31/201635.99M
11/2/201641.24M
3/10/201741.90M
4/28/201747.12M
7/31/201747.14M
10/30/201747.18M
3/9/201849.65M
5/4/201849.85M
8/2/201860.56M
11/2/201860.71M
2/15/201960.86M
4/30/201960.86M
7/31/201961.92M
7/26/2019773.02M
10/29/201962.79M
2/14/202065.55M
4/30/202073.12M
7/30/202073.48M
10/28/202073.60M
2/16/202174.63M
4/29/202175.09M
7/28/202175.50M
10/27/202175.55M
2/22/202279.16M
4/29/202279.42M
7/29/202279.81M
10/28/202281.16M
2/10/2023113.34M
4/28/2023114.01M
7/28/2023114.35M
10/27/2023114.53M
2/23/2024115.07M

Also see: KPTI Market Cap History
KPTI YTD Return
KPTI Historical Shares Outstanding:
+14.86% CAGR
KPTI Historical Shares Outstanding: +14.86% CAGR

Mouse over chart for data details
11/6/2013 ...2/23/2024
Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. We show 44 historical shares outstanding datapoints in our coverage of KPTI's shares outstanding history.

Understanding the changing numbers of KPTI shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like KPTI versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching KPTI by allowing them to research KPTI shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree KPTI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Karyopharm Therapeutics (KPTI) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

KRBP Shares Outstanding History
KRMD Shares Outstanding History
KRON Shares Outstanding History
KROS Shares Outstanding History
KRRO Shares Outstanding History
KRTX Shares Outstanding History
KRYS Shares Outstanding History
KTRA Shares Outstanding History
KTTA Shares Outstanding History
KTWO Shares Outstanding History
More Healthcare companies »

 

KPTI Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.